Search for dissertations about: "hK2"
Showing result 1 - 5 of 8 swedish dissertations containing the word hK2.
-
1. Human glandular kallikrein 2 (hK2) in prostate cancer: Clinical and Methodological studies
Abstract : Human glandular kallikrein 2 (hK2) is a predominantly prostate produced protein with many similarities to prostate-specific antigen (PSA). Just like for PSA elevated levels of hK2 can be found in men with protate cancer. We created an assay where hK2 in serum could reliably and with negligible cross-reactivity with PSA, be measured down to 0. READ MORE
-
2. Assessments of PSA Forms and hK2 as Very Early Predictors of Prostate Cancer
Abstract : Concentrations of prostate-specific antigen (PSA) and human kallikrein 2 (hK2) were investigated in blood samples that had been obtained from men who were diagnosed with prostate cancer (PCa) decades later. The studies were based on a cohort comprising 22,444 men who, in 1974?1986, were early middle aged and represented a non-PCa-screened population. READ MORE
-
3. The Kallikrein-Related Peptidases hK2 and PSA with Emphasis on Genetic Variation, Secretion, and Sperm Motility
Abstract : Prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) are secreted by the prostate into seminal plasma and through leakage into blood. This leakage increases rapidly in prostate disease, and PSA is used worldwide as a marker of prostate cancer. READ MORE
-
4. Human Glandular Kallikrein 2
Abstract : Human glandular kallikrein 2 (hK2) is a serine protease, which is predominantly expressed by the prostate gland and found in seminal plasma at mean levels of 6 mg/ml. It has 79% amino acid sequence identity with prostate-specific antigen (PSA or hK3). READ MORE
-
5. Radioimmunoimaging and Radioimmunotherapy of Prostate Cancer Preclinical evaluation of kallikrein related peptidase 2 targeting
Abstract : Prostate cancer is one of the major causes of cancer related deaths in men in Europe and the United States. In this doctoral thesis, radioimmunoimaging and -therapy of prostate cancer was investigated pre-clinically by targeting the human kallikrein-related peptidase 2 (hK2) with radiolabelled monoclonal antibodies. READ MORE